XLO · Xilio Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| GILEAD SCIENCES, INC. 10% Owner | ▲ Buy | Open Market | 9,105,451 Shares held | 12/18/2024 | View profile |
| Bain Capital Life Sciences Investors, LLC 10% Owner | ▲ Buy | Open Market | 2,805,413 Shares held | 12/10/2021 | View profile |
| RiverVest Venture Fund IV, L.P. 10% Owner | ▲ Buy | Open Market | 1,441,444 Shares held | 10/26/2021 | View profile |
| SV7 Impact Medicine Fund LP 10% Owner | ▼ Sell | Other | 1,301,132 Shares held | 10/26/2021 | View profile |
| Rock Springs Capital Management LP 10% Owner | ▲ Buy | Open Market | 1,256,472 Shares held | 10/26/2021 | View profile |
| James E. Flynn 10% Owner | ▲ Buy | Open Market | 1,143,972 Shares held | 10/26/2021 | View profile |
| BAY CITY CAPITAL LLC 10% Owner | ▲ Buy | Open Market | 1,129,490 Shares held | 10/26/2021 | View profile |
| Atlas Venture Fund XI, L.P. 10% Owner | ▼ Sell | Open Market | 734,546 Shares held | 2/8/2024 | View profile |
| Merck KGaA 10% Owner | ▼ Sell | Other | 680,825 Shares held | 10/26/2021 | View profile |
| Rene Russo PRESIDENT AND CEO | ▲ Buy | Option Exercise | 325,422 Shares held | 1/1/2026 | View profile |
| FIL Ltd | ▼ Sell | Other | 218,705 Shares held | 10/26/2021 | View profile |
| Alexandria Venture Investments, LLC 10% Owner | ▼ Sell | Other | 166,423 Shares held | 10/26/2021 | View profile |
| Katarina Luptakova CHIEF MEDICAL OFFICER | ▲ Buy | Option Exercise | 33,250 Shares held | 1/1/2026 | View profile |
| Christopher James Frankenfield Chief Financial Officer | ▼ Sell | Open Market | 24,766 Shares held | 1/2/2026 | View profile |
| James Samuel Shannon | ▲ Buy | Open Market | 10,000 Shares held | 3/26/2026 | View profile |
| Kevin M. Brennan SVP, FINANCE AND ACCOUNTING | ▼ Sell | Open Market | 6,371 Shares held | 1/2/2026 | View profile |
| FMR LLC | ▼ Sell | Other | 4,465 Shares held | 10/26/2021 | View profile |
Transaction History
| James Samuel Shannon | ▲ Buy | Open Market | 5,000 | $44K | 3/26/2026 |
| Kevin M. Brennan | ▼ Sell | Open Market | 1,826 | $1K | 1/2/2026 |
| Christopher James Frankenfield | ▼ Sell | Open Market | 7,030 | $5K | 1/2/2026 |
| Kevin M. Brennan | ▲ Buy | Option Exercise | 5,000 | — | 1/1/2026 |
| Rene Russo | ▲ Buy | Option Exercise | 44,250 | — | 1/1/2026 |
| Katarina Luptakova | ▲ Buy | Option Exercise | 16,625 | — | 1/1/2026 |
| Christopher James Frankenfield | ▲ Buy | Option Exercise | 19,375 | — | 1/1/2026 |
| James Samuel Shannon | ▲ Buy | Open Market | 25,000 | $17K | 6/17/2025 |
| Rene Russo | ▲ Buy | Open Market | 36,289 | $25K | 6/16/2025 |
| James Samuel Shannon | ▲ Buy | Open Market | 45,000 | $31K | 6/16/2025 |
| Christopher James Frankenfield | ▼ Sell | Open Market | 6,954 | $7K | 1/2/2025 |
| Kevin M. Brennan | ▼ Sell | Open Market | 1,803 | $2K | 1/2/2025 |
| Katarina Luptakova | ▲ Buy | Option Exercise | 16,625 | — | 1/1/2025 |
| Christopher James Frankenfield | ▲ Buy | Option Exercise | 19,375 | — | 1/1/2025 |
| Kevin M. Brennan | ▲ Buy | Option Exercise | 5,000 | — | 1/1/2025 |
| Rene Russo | ▲ Buy | Option Exercise | 44,250 | — | 1/1/2025 |
| GILEAD SCIENCES, INC. | ▲ Buy | Open Market | 1,759,978 | $1.8M | 12/18/2024 |
| Atlas Venture Fund XI, L.P. | ▼ Sell | Open Market | 733 | $469 | 2/8/2024 |
| Atlas Venture Fund XI, L.P. | ▼ Sell | Open Market | 267 | $171 | 2/8/2024 |
| Atlas Venture Fund XI, L.P. | ▼ Sell | Open Market | 1,540 | $1K | 1/12/2024 |
| Atlas Venture Fund XI, L.P. | ▼ Sell | Open Market | 560 | $465 | 1/12/2024 |
| Atlas Venture Fund XI, L.P. | ▼ Sell | Open Market | 1,566 | $1K | 1/11/2024 |
| Atlas Venture Fund XI, L.P. | ▼ Sell | Open Market | 569 | $495 | 1/11/2024 |
| Bain Capital Life Sciences Investors, LLC | ▲ Buy | Open Market | 21,812 | $209K | 12/10/2021 |
| Bain Capital Life Sciences Investors, LLC | ▲ Buy | Open Market | 3,188 | $33K | 12/10/2021 |
| Bain Capital Life Sciences Investors, LLC | ▲ Buy | Open Market | 4,011 | $39K | 12/9/2021 |
| Bain Capital Life Sciences Investors, LLC | ▲ Buy | Open Market | 13,458 | $129K | 12/8/2021 |
| James E. Flynn | ▲ Buy | Open Market | 387,500 | $6.2M | 10/26/2021 |
| James E. Flynn | ▲ Buy | Open Market | 387,500 | $6.2M | 10/26/2021 |
| RiverVest Venture Fund IV, L.P. | ▲ Buy | Open Market | 250,000 | $4.0M | 10/26/2021 |
| Rock Springs Capital Management LP | ▲ Buy | Open Market | 500,000 | $8.0M | 10/26/2021 |
| BAY CITY CAPITAL LLC | ▼ Sell | Other | 151,294 | — | 10/26/2021 |
| Atlas Venture Fund XI, L.P. | ▼ Sell | Other | 624,089 | — | 10/26/2021 |
| Atlas Venture Fund XI, L.P. | ▼ Sell | Other | 548,442 | — | 10/26/2021 |
| Atlas Venture Fund XI, L.P. | ▲ Buy | Open Market | 187,500 | $3.0M | 10/26/2021 |
| BAY CITY CAPITAL LLC | ▲ Buy | Open Market | 312,500 | $5.0M | 10/26/2021 |
| RiverVest Venture Fund IV, L.P. | ▼ Sell | Other | 832,120 | — | 10/26/2021 |
| SV7 Impact Medicine Fund LP | ▼ Sell | Other | 302,588 | — | 10/26/2021 |
| Rock Springs Capital Management LP | ▼ Sell | Other | 151,294 | — | 10/26/2021 |
| BAY CITY CAPITAL LLC | ▼ Sell | Other | 665,696 | — | 10/26/2021 |
| Rock Springs Capital Management LP | ▼ Sell | Other | 756,472 | — | 10/26/2021 |
| Atlas Venture Fund XI, L.P. | ▼ Sell | Other | 1,372,998 | — | 10/26/2021 |
| SV7 Impact Medicine Fund LP | ▼ Sell | Other | 302,588 | — | 10/26/2021 |
| SV7 Impact Medicine Fund LP | ▼ Sell | Other | 998,544 | — | 10/26/2021 |
| FMR LLC | ▼ Sell | Other | 4,465 | — | 10/26/2021 |
| Merck KGaA | ▼ Sell | Other | 264,765 | — | 10/26/2021 |
| FMR LLC | ▼ Sell | Other | 28,703 | — | 10/26/2021 |
| FMR LLC | ▼ Sell | Other | 372,215 | — | 10/26/2021 |
| RiverVest Venture Fund IV, L.P. | ▼ Sell | Other | 359,324 | — | 10/26/2021 |
| SV7 Impact Medicine Fund LP | ▼ Sell | Other | 998,544 | — | 10/26/2021 |
| FMR LLC | ▼ Sell | Other | 686,499 | — | 10/26/2021 |
| FMR LLC | ▼ Sell | Other | 789,473 | — | 10/26/2021 |
| FIL Ltd | ▼ Sell | Other | 218,705 | — | 10/26/2021 |
| Merck KGaA | ▼ Sell | Other | 416,060 | — | 10/26/2021 |
| James E. Flynn | ▼ Sell | Other | 756,472 | — | 10/26/2021 |
| James E. Flynn | ▼ Sell | Other | 756,472 | — | 10/26/2021 |
| Alexandria Venture Investments, LLC | ▼ Sell | Other | 166,423 | — | 10/26/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Xilio Therapeutics appoints Yariv J. Houvras as Chief Medical Officer
Xilio Therapeutics announced that Dr. Yariv J. Houvras, M.D., Ph.D., will serve as its new Chief Medical Officer. The appointment adds experienced clinical leadership to the company as it advances its therapeutic pipeline. This change comes while the stock is trading near the top of its 52‑week range, suggesting market attention to the leadership update.
Xilio Therapeutics appoints Yariv J. Houvras as Chief Medical Officer. Xilio Therapeutics announced that Dr. Yariv J. Houvras, M.D., Ph.D., will serve as its new Chief Medical Officer. The appointment adds experienced clinical leadership to the company as it advances its therapeutic pipeline. This change comes while the stock is trading near the top of its 52‑week range, suggesting market attention to the leadership update.